By Khazi Altaf Hussain, Managing Editor the Pharma times.in
The U.S. decision to impose a 100 % tariff on branded and patented pharmaceuticals, effective October 1, is a shock to the global health-economy balance. Though the move’s immediate target is high-margin branded imports, its ripple effects could reshape trade, pricing, and supply chains in ways nobody should dismiss.
To begin with, India is not a minor player. In 2024, the United States imported roughly US $12.73 billion worth of pharmaceutical products from India. Meanwhile, India’s exports of medicaments (in retail packings) to the U.S. were about US $8.44 billion in the same year. In FY 25, nearly 40 % of India’s pharmaceutical exports are estimated to have gone to the U.S. market. That level of exposure cannot be ignored.
The good news: the tariff is described as applying only to branded and patented drugs, leaving the bulk of India’s generics exports — India’s mainstay — ostensibly untouched. Analysts believe this carve-out limits immediate disruption. But “for now” is always a fragile phrase in global trade.
Still, risks loom:
Upward pricing pressure in the U.S. If importers pass on the tariff burden, patients and health insurers will feel the pinch.
Supply-chain reconfiguration may push firms to relocate or source drugs from other jurisdictions or set up local manufacturing just to qualify for exemptions.
Policy creep: The exception today may be expanded tomorrow. There’s a real fear that sophisticated generics, biosimilars, or borderline molecules might be pulled under the tariff net later.
Investor jitters: Indian pharma stocks already dropped ~2–3 % after the announcement.
Export competitiveness squeeze: Even if generics are spared now, the cost of APIs (often imported) can rise, tightening margins.
So where must India pivot?
1. Deepen API self-reliance – move up the value chain, reducing import dependence on key raw materials.
2. Ramp up innovation – build stronger capabilities in biosimilars, new drug development, and niche segments.
3. Diversify export destinations – expand trade ties with Africa, Latin America, ASEAN, and EU, reducing overexposure to U.S. policy shifts.
4. Engage diplomatically – urgent high-level pharma diplomacy is needed to press the U.S. to avoid disproportionate harm to generics and to ensure rules are transparent and fair.
The tariff salvo is a wake-up call. It’s a reminder that dependence (even in healthcare) carries vulnerability. What India must now do is not just react — it must reimagine. If we craft an adaptive, resilient pharma ecosystem, today’s shock could catalyze tomorrow’s leap
